The Klein Law Firm
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, ATHA and YMM
NEW YORK, NY / ACCESSWIRE / July 15, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Frequency Therapeutics, Inc. (NASDAQ:FREQ)
Class Period: November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline: August 2, 2021
The complaint alleges that throughout the class period Frequency Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
Learn about your recoverable losses in FREQ: https://www.kleinstocklaw.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?id=17674&from=1
Athira Pharma, Inc. (NASDAQ:ATHA)
This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.
Lead Plaintiff Deadline: August 24, 2021
The ATHA lawsuit alleges that throughout the class period, Athira Pharma, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.
Learn about your recoverable losses in ATHA: https://www.kleinstocklaw.com/pslra-1/athira-pharma-inc-loss-submission-form?id=17674&from=1
Full Truck Alliance Co. Ltd. (NYSE:YMM)
This lawsuit is on behalf of persons who purchased or otherwise acquired Full Truck's securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Full Truck's June 2021 initial public offering.
Lead Plaintiff Deadline: September 10, 2021
The complaint alleges that throughout the class period Full Truck Alliance Co. Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) Full Truck's apps Yunmanman and Huochebang would face an imminent cybersecurity review by the Chinese government; (2) the Chinese government would require Full Truck to suspend new user registration; (3) FTA needed to conduct a "comprehensive self-examination of any cybersecurity risks"; (4) Full Truck needed to "continue to improve its cybersecurity systems and technology capabilities"; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times and negligently prepared.
Learn about your recoverable losses in YMM: https://www.kleinstocklaw.com/pslra-1/full-truck-alliance-co-ltd-loss-submission-form?id=17674&from=1To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
CTT Systems AB21.10.2021 15:03:07 CEST | Press release
Changes in the Nomination Committee for CTT Systems AB
ITOCO Inc.21.10.2021 13:32:20 CEST | Press release
ITOCO Welcomes Maria Teresa Tattersfield Yarza to Its Board of Directors and Carbon Credit Advisory Board
XVIVO Perfusion AB21.10.2021 08:06:47 CEST | Press release
XVIVO Presents Interim Report January-September 2021
Ximen Mining Corp.21.10.2021 05:31:49 CEST | Press release
Ximen Mining Corp Closes Recently Announced Financings
Champions Oncology, Inc.20.10.2021 16:28:12 CEST | Press release
Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus
Physitrack20.10.2021 09:12:03 CEST | Press release
Physitrack PLC – Interim report: December 2020 – August 2021
Re:NewCell AB (publ)19.10.2021 14:17:20 CEST | Press release
Renewcell and Kelheim Fibres Form Collaboration to Establish a European Closed Loop for Fashion
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom